From the Journals
HS Linked to Higher Self-Harm, Suicide Risk
-
By
-
March 13, 2026
-
2 min
By
March 13, 2026
Investigators report high 90-day response rates with no persistent adverse events.
March 13, 2026
Phase III CUPID-C trial evaluates biologic therapy in patients with chronic spontaneous urticaria uncontrolled by antihistamines.
March 12, 2026
Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.
March 12, 2026